Literature DB >> 30159587

NLRP3 deficiency accelerates pressure overload-induced cardiac remodeling via increased TLR4 expression.

Fangfang Li1,2, Hao Zhang1,2, Lu Yang1,2, Hui Yong1,2, Qingqing Qin1,2, Mengtong Tan1,2, Luhong Xu1,2, Kai Liang1,2, Jing Zong3,4, Wenhao Qian5,6.   

Abstract

NLRP3, a member of the nucleotide-binding oligomerization domain (NOD)-like receptor family, is involved in cardiac inflammation. However, the functional role of NLRP3 in cardiac remodeling is not clear. To investigate the roles of NLRP3 in pressure overload-induced cardiac remodeling, NLRP3 knockout and wild-type mice were subjected to aortic banding to induce cardiac remodeling. The data showed that NLRP3 expression was downregulated in the remodeling process. NLRP3 deficiency accelerated cardiac hypertrophy, fibrosis, and inflammation responses with deteriorating cardiac dysfunction in the pressure overload-induced cardiac remodeling mouse model. Neonatal rat cardiomyocytes were isolated and stimulated with phenylephrine (PE). We identified NLRP3 as a negative regulator of cardiomyocyte remodeling in PE-stimulated cardiomyocyte remodeling using adenovirus-NLRP3 and NLRP3 siRNA. Mechanistically, we found that the expression of Toll-like receptor (TLR) 4 was upregulated in NLRP3-deficient mouse hearts and PE-stimulated cardiomyocytes. NLRP3 knockout mice subjected to a TLR4 inhibitor revealed a relieved cardiac remodeling response with improved cardiac dysfunction. Our data suggested that NLRP3 could be a therapeutic target for cardiac remodeling and heart failure. KEY MESSAGES: NLRP3 expression was downregulated in the remodeling process. NLRP3 deficiency accelerated pressure overload-induced cardiac remodeling. NLRP3 acted as a negative regulator of cardiomyocyte remodeling via downregulating TLR4.

Entities:  

Keywords:  Aortic banding; Cardiac remodeling; NLRP3; TLR4

Mesh:

Substances:

Year:  2018        PMID: 30159587     DOI: 10.1007/s00109-018-1691-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  25 in total

1.  The NLRP3 inflammasome and diabetic cardiomyopathy : editorial to: "Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model" by Beibei Luo et al.

Authors:  Lalit P Singh
Journal:  Cardiovasc Drugs Ther       Date:  2014-02       Impact factor: 3.727

Review 2.  The role of Toll-like receptor 4 (TLR4) in cardiac ischaemic-reperfusion injury, cardioprotection and preconditioning.

Authors:  Sam Man Lee; Mark Hutchinson; David A Saint
Journal:  Clin Exp Pharmacol Physiol       Date:  2016-09       Impact factor: 2.557

Review 3.  The NLRP3 inflammasome in acute myocardial infarction.

Authors:  Stefano Toldo; Antonio Abbate
Journal:  Nat Rev Cardiol       Date:  2017-11-16       Impact factor: 32.419

Review 4.  Mechanisms contributing to cardiac remodelling.

Authors:  Qing-Qing Wu; Yang Xiao; Yuan Yuan; Zhen-Guo Ma; Hai-Han Liao; Chen Liu; Jin-Xiu Zhu; Zheng Yang; Wei Deng; Qi-Zhu Tang
Journal:  Clin Sci (Lond)       Date:  2017-08-24       Impact factor: 6.124

Review 5.  Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Authors:  Bassant Orabi; Rasha Kaddoura; Amr S Omar; Cornelia Carr; Abdulaziz Alkhulaifi
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

6.  Aucubin protects against pressure overload-induced cardiac remodelling via the β3 -adrenoceptor-neuronal NOS cascades.

Authors:  Qing-Qing Wu; Yang Xiao; Ming-Xia Duan; Yuan Yuan; Xiao-Han Jiang; Zheng Yang; Hai-Han Liao; Wei Deng; Qi-Zhu Tang
Journal:  Br J Pharmacol       Date:  2018-03-25       Impact factor: 8.739

Review 7.  How cardiomyocytes sense pathophysiological stresses for cardiac remodeling.

Authors:  Zaffar K Haque; Da-Zhi Wang
Journal:  Cell Mol Life Sci       Date:  2016-10-06       Impact factor: 9.261

Review 8.  NLRP3: A promising therapeutic target for autoimmune diseases.

Authors:  Hui-Hui Shen; Yue-Xin Yang; Xiang Meng; Xiao-Yun Luo; Xiao-Mei Li; Zong-Wen Shuai; Dong-Qing Ye; Hai-Feng Pan
Journal:  Autoimmun Rev       Date:  2018-05-03       Impact factor: 9.754

9.  Intermedin1-53 Protects Cardiac Fibroblasts by Inhibiting NLRP3 Inflammasome Activation During Sepsis.

Authors:  Di Wu; Lin Shi; Pengyang Li; Xianqiang Ni; Jinsheng Zhang; Qing Zhu; Yongfen Qi; Bin Wang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 10.  Oxidative Stress and NLRP3-Inflammasome Activity as Significant Drivers of Diabetic Cardiovascular Complications: Therapeutic Implications.

Authors:  Arpeeta Sharma; Mitchel Tate; Geetha Mathew; James E Vince; Rebecca H Ritchie; Judy B de Haan
Journal:  Front Physiol       Date:  2018-02-20       Impact factor: 4.566

View more
  9 in total

Review 1.  Emerging Roles of Inflammasomes in Cardiovascular Diseases.

Authors:  Yingnan Liao; Kui Liu; Liyuan Zhu
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

Review 2.  Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases.

Authors:  Na An; Yonghong Gao; Zeyu Si; Hanlai Zhang; Liqin Wang; Chao Tian; Mengchen Yuan; Xinyu Yang; Xinye Li; Hongcai Shang; Xingjiang Xiong; Yanwei Xing
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

Review 3.  NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases.

Authors:  Yucheng Wang; Xiaoxiao Liu; Hui Shi; Yong Yu; Ying Yu; Minghui Li; Ruizhen Chen
Journal:  Clin Transl Med       Date:  2020-04-09

Review 4.  Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19 Patients.

Authors:  Lealem Gedefaw; Sami Ullah; Polly H M Leung; Yin Cai; Shea-Ping Yip; Chien-Ling Huang
Journal:  Cells       Date:  2021-04-16       Impact factor: 6.600

5.  MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure.

Authors:  Xiaobo Jiang; Fan Yang; Dengke Ou; Luyong Huang; Hongfei Li; Mingjian Lang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

6.  Identification of key genes for hypertrophic cardiomyopathy using integrated network analysis of differential lncRNA and gene expression.

Authors:  Jing Cao; Lei Yuan
Journal:  Front Cardiovasc Med       Date:  2022-08-04

7.  Relationship between Innate Immune Response Toll-Like Receptor 4 (TLR-4) and the Pathophysiological Process of Obesity Cardiomyopathy.

Authors:  Pedro Henrique Rizzi Alves; Artur Junio Togneri Ferron; Mariane Róvero Costa; Fabiana Kurokawa Hasimoto; Cristina Schmitt Gregolin; Jéssica Leite Garcia; Dijon Henrique Salomé de Campos; Antônio Carlos Cicogna; Letícia de Mattei; Fernando Moreto; Silméia Garcia Zanati Bazan; Fabiane Valentini Francisqueti-Ferron; Camila Renata Corrêa
Journal:  Arq Bras Cardiol       Date:  2021-07       Impact factor: 2.000

8.  Zinc Finger Protein ZBTB20 protects against cardiac remodelling post-myocardial infarction via ROS-TNFα/ASK1/JNK pathway regulation.

Authors:  Fangfang Li; Yiming Yang; Chuanyou Xue; Mengtong Tan; Lu Xu; Jianbo Gao; Luhong Xu; Jing Zong; Wenhao Qian
Journal:  J Cell Mol Med       Date:  2020-10-16       Impact factor: 5.295

9.  Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy.

Authors:  Sai Ma; Jing Feng; Xiuyu Lin; Jing Liu; Yi Tang; Shinan Nie; Jianbin Gong; Lei Wang
Journal:  Oxid Med Cell Longev       Date:  2021-09-15       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.